Infertility Clinical Trial
Official title:
Natural Cycle/Progesterone Fortified Protocol for Endometrial Preparation for Frozen/Thawed Embryo Transfer
This is a pilot study of a novel protocol for preparation of the endometrium for frozen/thawed embryo transfer whereby estrogen is not administered during the proliferative phase and progesterone is administered through vaginal suppositories in accordance with endometrial thickness only, disregarding the day of ovulation. Progesterone supplementation commences once the endometrium is at least 7 mm, a follicle is demonstrated on TVS, and ovulation has not yet taken place. The day of ET is scheduled according to the unit's working days and progesterone suppositories are commenced 48 hours before the scheduled embryo transfer.
Natural cycle/progesterone fortified protocol for endometrial preparation for frozen/thawed
embryo transfer Study type: Descriptive pilot study of a novel protocol for endometrial
preparation for frozen/thawed embryo transfer Introduction: In the process of in-vitro
fertilization (IVF) cycles embryos are frequently cryopreserved for future attempts at
conception. In order for these embryos to take root in the uterus, the endometrial lining
must be made "receptive" to embryo implantation.
During the natural reproductive cycle, this process takes place in two stages. During the
endometrium's proliferative phase, which takes place during the first 14 days of a 28 day
cycle, estradiol is produced by the growing follicle whereby the thin endometrium remaining
after the menstrual cycle proliferates to a width of between 7 to 14 mm on average, attains a
triphasic appearance on ultrasound and acquires receptors for progesterone. After ovulation,
the ovarian follicle transforms to a corpus luteum which produces progesterone. At this
stage, exposure to progesterone transforms the endometrium to one which is receptive to
embryo implantation. There is a minimum level of progesterone and a minimum time of exposure
which is necessary to transform the endometrium to a receptive one while prolonged
progesterone exposure renders the endometrium hostile to implantation. The boundaries of this
time zone are referred to as the window of implantation. The length of time of this window is
unknown.
There are two strategies for returning frozen/thawed embryos to the uterus in women with
regular menstrual cycles.
1. The natural cycle: In our facility embryos are cryopreserved 48-72 hours after
fertilization. In the natural cycle protocol women are monitored for estradiol,
progesterone and LH levels in the blood and endometrial thickness and follicle
development. The thawed embryos are transferred to the uterus 48-72 hours after presumed
ovulation and the rise of progesterone
2. Hormone replacement protocol: The patient is given beta estradiol 2mg three times a day
(Estrofem - Novo Nordisk) from the first day of the menstrual cycle. This prevents
indigenous follicle development on the one hand, but is sufficient to prepare the
endometrium. When the endometrium is at least 7 mm thick vaginal suppositories of
progesterone are administered 100 mg tid (Endometrin - Lapidot) for 48 hours after which
the embryos are transferred. If the endometrium fails to reach 7 mm, additional estrogen
is added. Since there is no corpus luteum in this protocol, estradiol and progesterone
supplementation must be given until the placenta produces these hormones in sufficient
quantities. We maintain hormonal support until 11.6 weeks of gestation in cycles where
pregnancy is attained.
The advantage of the natural cycle is that there is no need to take hormones. Nevertheless,
it should be noted that even though progesterone supplementation is not necessary for the
natural cycle protocol, many IVF units add progesterone support after embryo transfer. A
recent study demonstrated that adding progesterone to the natural cycle increased the live
birth rate (Bjuresten et al. 2011). Patients were monitored from day 10 to 14 for follicular
development after which daily home urinary kits were provided to detect the LH surge. Three
days after detection of the LH surge thawed embryos were transferred and patients in the
study group commenced taking vaginal progesterone.
The disadvantages of the natural cycle is that the IVF unit must be prepared to perform an
embryo transfer on every day of the week including days on which the unit is closed, in
accordance with the day of ovulation. Delaying embryo transfer to the unit's work schedule
may cause the embryo transfer to take place outside of the endometrium's window of
implantation.
In the hormone replacement protocol the physician determines the day the patient begins
progesterone supplementation, and therefore the day of embryo transfer can be scheduled
according to the units work load. Furthermore there is no need for blood tests during patient
monitoring. Ultrasound monitoring can usually be limited to two or three visits. The hormone
replacement protocol is the protocol of choice in our unit.
Rationale:
Ovulation is not essential for embryo implantation in the endometrial lining as demonstrated
in the hormone replacement protocol. In the proposed protocol the developing follicle
stimulates endometrial growth and progesterone is commenced once endometrial growth reaches
at least 7 mm and the dominant follicle has been established, regardless of when ovulation
occurs. Embryo transfer is performed 48 hours after beginning progesterone. By dissociating
the protocol from the day of ovulation greater leeway is achieved in choosing the day of
embryo transfer.
Objectives:
This is a pilot study of a novel protocol for preparation of the endometrium for
frozen/thawed embryo transfer whereby estrogen is not administered during the proliferative
phase and progesterone is administered through vaginal suppositories in accordance with
endometrial thickness only, disregarding the day of ovulation. The primary outcome is the
biochemical pregnancy rate. Secondary outcomes include the clinical pregnancy rate and
ongoing pregnancy rate.
Intervention: We propose a protocol for endometrial preparation for frozen/thawed embryo
transfer which combines the advantages of both protocols. Patients do not receive estradiol
and therefore ovarian follicle production is not suppressed. Progesterone supplementation
commences once the endometrium is at least 7 mm, a follicle is demonstrated on TVS, and
ovulation has not yet taken place. The day of ET is scheduled according to the unit's working
days and progesterone suppositories are commenced 48 hours before the scheduled embryo
transfer. In order to ensure synchronization between the endometrium and the embryos, embryo
transfer of 48 hour embryos will be transferred 48 hours after progesterone therapy. This is
not different from our current practice.
Like the natural cycle protocol, we allow ovulation to take place but we are not dependent on
the day of ovulation to dictate to us the day of embryo transfer, as long as we begin
progesterone supplementation before or at the same time as the natural rise of progesterone
which accompanies ovulation. The progesterone supplementation dose is identical to the
standard protocol so that even if ovulation is suppressed the luteal support is adequate.
In this protocol there is no need for daily blood and ultrasound studies. For most patients,
one visit around day 10-13 will probably suffice to schedule the embryo transfer.
Progesterone supplementation can be less intensive and estrogen supplementation unnecessary.
Recruitment:
Recruitment for the study will be done by the investigators who are all senior ob/gyn
specialists at the IVF unit. Patients to be recruited are those women who have cryopreserved
embryos in our unit and who request a frozen thawed embryo replacement cycle. No recruitment
outside of the unit will take place, no transfer of frozen embryos from other units will be
included and therefore no advertising is necessary.
Inclusion criteria:
1. Women younger than 39 at the time of cryopreservation
2. Regular menstrual cycles of at least 26 days and at most 32 days.
3. Women with no more than 3 failed prior embryo transfers
4. Patients with embryos cryopreserved 48 hours after ovum pick up Exclusion and withdrawal
criteria
1. Women with known uterine malformations or significant myomas 2. Women with elevated
Progesterone of at least 1.5 ng/mL for the duration of more than 72 hours before embryo
transfer can be performed 3. Women suspected of having endometrial pathology based on
previous treatment cycles i.e. "thin endometrium", polyps, adhesions 4. Women whose embryos
did not survive the thawing process, i.e. no embryos available for transfer after thawing 5.
Women without follicular development
Protocol:
A blood sample for estradiol, progesterone and LH will be taken on days 10 - 14 of a 28 day
cycle as well as a TVS study of the endometrial thickness and ovarian follicles. The day of
the first visit can be adjusted according to the length of the cycle.
Based on these tests the physician will determine if there is active follicle formation prior
to ovulation. Evidence of active follicle formation includes a clear follicle of at least 12
mm and estradiol of at least 80 pg/ml. If the endometrium is at least 7 mm, ET will be
scheduled. If the endometrium is less than 7 mm the patient will be invited for a second
visit 1-3 days later.
Should there be evidence of ovulation having already taken place, such as a progesterone
level over 1.5 ng/ml and sonographic evidence of a corpus luteum, then the cycle will be
cancelled.
If there is no evidence of follicular activity at the first visit after menstruation; i.e.
estradiol under 80 pg/ml and no follicle demonstrated on ultrasound, the patient will be
withdrawn from the study.
Progesterone suppositories (Endometrin), 100 mg 3 times a day will commence 48 hours before
scheduled embryo transfer until the day of the pregnancy test 14 days later. All embryo
transfers will be done under abdominal ultrasound guidance. At the time of embryo we will
record the size of the leading follicle and whether it has attributes of a corpus luteum.
Once pregnancy is confirmed progesterone support will be continued until 11.6 weeks three
times a day. Blood samples and sonographic studies will be done as needed until embryo
transfer. HCG, progesterone and estradiol will be measured 14 days after embryo transfer and
16-17 days after should a pregnancy be detected. An ultrasound will be performed at 5-6 weeks
to confirm the presence of a gestational sac and at 6-7 weeks to confirm a heartbeat. Data
will be collected until pregnancy termination or delivery.
Sample size:
The biochemical pregnancy rate for FET in our unit for patients of this age group is 24%.
A sample size of 40 patients will provide 13% accuracy for pregnancy rate. Recruitment will
end after 40 patients have completed the protocol up to the stage of embryo transfer. Up to
75 women will be recruited in order to assure that 40 patients complete the protocol. The
primary endpoint is the biochemical pregnancy rate. Secondary endpoints include implantation
rate and clinical pregnancy rate. For the purposes of comparison a cohort of patients not in
the study undergoing the traditional hormone replacement preparation will be analyzed.
All patient data will be kept confidential by all researchers. Patient research files will be
kept in a locked closet in the IVF unit. Patients names and ID numbers will be replaced by
patient codes in the database before submitting for statistical analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A |